Literature DB >> 35932000

The clinical features of late postoperative cholangitis following pancreaticoduodenectomy brought on by conditions other than cancer recurrence: a single-center retrospective study.

Yasuhiro Kihara1, Hiroshi Yokomizo2.   

Abstract

BACKGROUND: Postoperative cholangitis is a late complication of pancreaticoduodenectomy (PD). This study aimed to elucidate the pathogenesis of post-PD cholangitis (PPDC) and explore its optimal treatment.
METHODS: We retrospectively analyzed 210 patients who underwent PD at our institute between 2009 and 2018. Patients who underwent follow-up for less than 1 year or had cholangitis caused by cancer recurrence were excluded from the analysis. Diagnostic criteria for cholangitis and its severity were determined based on the classification of acute cholangitis provided by the 2018 Tokyo Guidelines (TG18).
RESULTS: PPDC occurred in 19 (11%) of the 176 included patients. Of these 19 patients, nine experienced more than one episode of cholangitis (total episodes, 36). For 14 patients (74%), the first episode of PPDC occurred within two years after surgery. Based on the TG18, 21 episodes were mild and 15 episodes were moderate; none were severe. Blood culture test results were positive for 16 of 24 episodes. Most patients were hospitalized and treated with intravenous antibiotics (median, seven days). The blood test values improved promptly after treatment was started. Four patients with recurrent cholangitis underwent endoscopic examination, and three of them had anastomotic stenosis of the hepaticojejunostomy. The univariate and multivariate analyses did not indicate any significant predictive factors for PPDC development.
CONCLUSION: Mild and moderate PPDC occurred and improved with short-term antimicrobial treatment. Temporary reflux into the intrahepatic bile ducts may have been the cause of PPDC while anastomotic stenosis may be involved in recurrent cases.
© 2022. The Author(s).

Entities:  

Keywords:  Pancreaticoduodenectomy; Postoperative cholangitis; Tokyo Guidelines 2018

Mesh:

Year:  2022        PMID: 35932000      PMCID: PMC9356454          DOI: 10.1186/s12893-022-01752-3

Source DB:  PubMed          Journal:  BMC Surg        ISSN: 1471-2482            Impact factor:   2.030


Background

Improved surgical techniques and postoperative management have enhanced the short-term postoperative outcomes of pancreaticoduodenectomy (PD) [1, 2]. As a result, long-term outcomes have become increasingly important. Postoperative cholangitis is one of the major late complications affecting long-term survivors after PD [3-5]. Common acute cholangitis, in the absence of surgical manipulation of the biliary system, is caused by stones or tumors obstructing the bile flow. Bile stasis leads to bacterial growth, and the increased pressure in the biliary tract allows bacteria and inflammatory substances to enter the veins, causing a systemic inflammatory reaction, such as sepsis. If not treated appropriately, common acute cholangitis can be fatal. In contrast, post-PD cholangitis (PPDC) is suspected to be caused by digestive fluid reflux into the intrahepatic bile duct (IHBD), and bile congestion is attributable to anastomotic stricture [3-5]. Resection of the distal bile duct, including the sphincter of Oddi, in PD, may weaken the anti-reflux mechanism and increase the risk of digestive juice reflux into the IHBD. Additionally, anastomosis of hepaticojejunostomy may result in stenosis, which could cause bile stasis [3-5]. These findings suggest that cholangitis is more likely to occur in the post-PD state. Although guidelines, such as the Tokyo Guidelines (TG), have been well established for common acute cholangitis, there are no specific guidelines for PPDC. Currently, the diagnosis and treatment of PPDC are based on the guidelines for common acute cholangitis. However, the anatomy of the biliary system is modified by surgery; therefore, the clinical course may be different from that of common acute cholangitis. This study aimed to elucidate the pathogenesis of post-PD cholangitis by examining its clinical features and explore its optimal treatment. These results have not been previously described in detail.

Methods

Patients

In this study, we enrolled patients who underwent PD at our institution between January 2009 and August 2018. Preoperative and postoperative clinical data were retrospectively collected. The Clinical Ethics Committee of our institute approved this study (permission no. 374), and the requirement for informed consent was waived due to the retrospective design of the study. We excluded patients from the analysis if they were followed up for less than one year due to death or unsuccessful follow-up (27 patients). In addition, we excluded cases of postoperative cholangitis caused by cancer recurrence (7 patients) and those with postoperative cholangitis that developed within one month after surgery (not applicable). Finally, 157 patients in the group without PPDC and 19 patients in the group with PPDC were included in the analysis (Fig. 1).
Fig. 1

Patient enrollment flowchart

Patient enrollment flowchart

Diagnostic criteria for and severity classification of postoperative cholangitis

Based on literature review and expert consensus at the International Consensus Conference on the Management of Acute Cholangitis and Cholecystitis, diagnostic criteria for common acute cholangitis were first defined in 2007 [6]. The TG were revised in 2013 [7, 8] and 2018 [9, 10]. Therefore, we evaluated PPDC according to the criteria for common acute cholangitis proposed by the 2018 Tokyo Guidelines (TG18). The diagnostic criteria and severity classifications are listed in Table 1. In this study, suspected diagnoses based on the TG18 were also classified as cholangitis.
Table 1

Diagnosis criteria and severity classification of PPDC based on TG18

A. Systemic inflammation
 A-1. Fever and/or shaking chills
 A-2. Laboratory data: evidence of inflammatory response
B. Cholestasis
 B-1. Jaundice
 B-2. Laboratory data: abnormal liver function tests
C. Imaging
 C-1. Biliary dilatation
 C-2. Evidence of the etiology on imaging (stricture, stone, stent etc
Suspected diagnosis: one item in A + one item in either B or C
Definite diagnosis: one item in A, one item in B and one item in C
Thresholds:
A-1FeverBT > 38 °C
A-2Evidence of inflammatory response

WBC counts: < 4000 or > 10,000 /μL

CRP: > 1.0 mg/dL

B-1JaudiceT-bil: > 2.0 mg/dL
B-2Abnormal liver functionALP, γ-GTP, AST, ALT: > 1.5 times the institutional standard values

PPDC post pancreaticoduodenectomy cholangitis, TG18 Tokyo Guideline 2018, BT body temperature, WBC white blood cells, CRP C-reactive protein, T-bil Total bilirubin, ALP alkaline phosphate, γ-GTP gamma-glutamyl transpeptidase, AST aspartate aminotransaminase, ALT alanine aminotransaminase

Diagnosis criteria and severity classification of PPDC based on TG18 WBC counts: < 4000 or > 10,000 /μL CRP: > 1.0 mg/dL Presenting with two of the following events: Age ≥ 75 BT ≥ 39 ºC WBC count < 4000 or 12,000 T-bil ≥ 5 mg/dl Serum albumin level 0.73 × the standard value PPDC post pancreaticoduodenectomy cholangitis, TG18 Tokyo Guideline 2018, BT body temperature, WBC white blood cells, CRP C-reactive protein, T-bil Total bilirubin, ALP alkaline phosphate, γ-GTP gamma-glutamyl transpeptidase, AST aspartate aminotransaminase, ALT alanine aminotransaminase

Perioperative management

PD has been often indicated for tumors of the pancreatic head region with obstructive jaundice. For such cases in our study, endoscopic retrograde biliary drainage was performed preoperatively by a gastroenterologist to reduce jaundice. Prophylactic antibiotics were administered at the time of surgery, and the same antibiotics were continued until the first postoperative day.

Surgical procedure

All surgeries evaluated in this study were performed by experienced hepatobiliary pancreatic surgeons. The PD procedure performed at our institute was based on subtotal stomach-preserving PD, whereby the stomach antrum is resected to preserve most of the stomach. Reconstruction was performed using the modified Child method. After resection, anastomoses were constructed using a single jejunal loop that was brought through the resected ligament of Treitz. First, pancreaticojejunostomy was performed in an end-to-side manner. Subsequently, hepaticojejunostomy was performed in an end-to-side manner using a single layer of interrupted sutures. If the diameter of the remnant bile duct was small, then an internal or external drainage tube (6-Fr silicon tube) was placed at the anastomosis at the surgeon's discretion. Finally, with the patient in the retrocolic position, side-to-side gastrojejunostomy was performed approximately 35 cm downstream from the hepaticojejunostomy. Braun’s anastomosis was not added to the routine.

Perioperative factors

Operative time, blood loss, blood transfusion, postoperative pancreatic fistula (POPF), bile leakage, and delayed gastric emptying (DGE) were extracted as perioperative factors. POPF was evaluated using the revised classification of the International Study Group of Pancreatic Fistula [11]; bile leakage was defined according to the guidelines of the International Study Group of Liver Surgery [12]. The DGE was evaluated using the classification of International Study Group of Pancreatic Surgery in 2007 [13].

Outpatient management

Patients underwent postoperative follow-up assessments, including blood tests and imaging studies, at the outpatient clinic every four to six months. Patients with symptoms, such as fever, visited the emergency room or outpatient clinic. Blood tests, blood culture tests, and imaging studies were performed based on the discretion of the examining physician. When cholangitis was diagnosed, patients were often admitted to the general medicine ward and treated with intravenous antibacterial therapy. Pneumobilia was considered positive if the findings were found on imaging studies (computed tomography or ultrasonography) at postoperative follow-up.

Statistical analysis

Continuous variables are expressed as the mean or median, standard deviation, and range. Categorical data were analyzed using either the chi-square test or Fisher’s exact test. Further, continuous data were analyzed using Student's t-test or Wilcoxon’s rank sum test for unpaired data, and paired t-test or Wilcoxon’s signed-rank test for paired data, as appropriate. A logistic regression analysis was performed in the multivariate assessment to determine independent risk factors. Baseline variables (P < 0.20 in the univariate analysis) were included in the multivariate analysis. Furthermore, preoperative biliary drainage [14] and postoperative pneumobilia [15], which have been previously reported as risk factors for severe complication after PD, were included in the multivariate model. All statistical analyses were performed using the JMP® Pro 14.2.0 software (SAS Institute Inc., Cary, NC, USA) and R version 4.0.0 (The R Foundation for Statistical Computing, Vienna, Austria). All analyses were two-tailed, and P < 0.05 was considered statistically significant.

Results

The clinical characteristics of 176 patients are summarized in Table 2. The median age of these 176 patients was 70 years (range, 34–86 years); 63% were men; and the mean body mass index was 22.9 kg/m2. The most common disease associated with PD was pancreatic carcinoma (45%). Jaundice was detected in 47% of the patients, and preoperative biliary drainage, including prophylactic procedures, was performed in 59% of the patients. Preoperative cholangitis was detected in 20% of patients.
Table 2

Clinical characteristics of patients (n = 176)

CharacteristicPatients (n)Percent
Patient factors
Age, years
 Median (range)70 (34–86)
 Interquartile range63–76
Sex
 Male11063
 Female6637
Body mass index (kg/m2)
 Mean (SD)22.9 (3.2)
 Range15.4–35.3
ASA-PS2715
 I
 II13878
 III105.6
 IV10.5
Diabetes mellitus2816
Diagnosis
 Pancreatic carcinoma7945
 Cholangiocarcinoma4727
 Carcinoma of the ampulla of Vater2212
Others2816
Jaundice8247
Preoperative biliary drainage10459
Preoperative cholangitis3520
Postoperative cholangitis1911
Operative factors
Operative time (min)
 Median (range)451 (278–738)
 Interquartile range381–497
Blood loss (ml)
 Median (range)594 (10–2450)
 Interquartile range330–1195
Blood transfusion3319
Width of remnant bile duct (mm)
 Median (range)10 (4–40)
 Interquartile range8–12
Biliary stenting9453
Postoperative factors
POPF
 Grade B or C8448
Bile leakage42.2
DGE95.1
Postoperative pneumobilia13276
Observation period (month)
 Median (range)35 (11–115)
 Interquartile range18–58

SD standard deviation; POPF postoperative pancreatic fistula; DGE delayed gastric empty; ASA-PS American Society of Anesthesiologists Physical Status

Clinical characteristics of patients (n = 176) SD standard deviation; POPF postoperative pancreatic fistula; DGE delayed gastric empty; ASA-PS American Society of Anesthesiologists Physical Status Details of the PPDC are presented in Table 3. PPDC occurred in 19 of 176 (11%) patients; of these, nine had recurrent PPDC, resulting in a total of 36 episodes. Of the 19 patients who had PPDC, 14 (73%) experienced the first episode within two years after surgery. Based on the TG18, 21 of 36 (58%) cases were classified as mild and 15 of 36 (42%) cases were moderate; none of the cases were severe.
Table 3

Details of PPDC

Number of affected patients19/176 (11%)
Total events of PPDC36
Number of episodes of PPDCPatients (n = 19)
 110
 23
 35
 51
Time from surgery to first onset (month)Patients (n = 19)
 ≤ 2414
 > 245
Severity according to TG18Total events (n = 36)
 Mild21 (58%)
 Moderate15 (42%)
 Severe0

PPDC post pancreaticoduodenectomy cholanitis, TG18 Tokyo Guideline 2018

Details of PPDC PPDC post pancreaticoduodenectomy cholanitis, TG18 Tokyo Guideline 2018 The results of the blood tests showed changes in the white blood cell counts, alkaline phosphatase levels, and gamma-glutamyl transpeptidase values, before and after treatment was started. The first blood test was performed a median of three days later (range, 1–7 days) after the treatment began. Although the initial treatment was limited to antibiotics only, all of the blood tests for this cohort showed significant improvement after starting treatment (Fig. 2).
Fig. 2

Changes in the blood test values of (a) WBC, (b) ALP, and (c) γ-GTP at the onset of post-PD cholangitis and after starting the initial treatment. Blood test results showed changes in the (a) white blood cell (WBC) counts, (b) alkaline phosphatase (ALP) levels, and (c) gamma-glutamyl transpeptidase (γ-GTP) values at the onset of post-pancreaticoduodenectomy cholangitis (PPDC) and after starting the initial treatment. For WBC counts, the median at the onset of PPDC and first blood test after starting treatment were 10,385 (range: 4120‒21,690) and 6000 (range: 2570‒17,260), respectively (a). The Wilcoxon signed-rank sum test for the two corresponding groups showed a statistically significant difference with P = 1.2 × 10–6 (a). For ALP level, the median at the onset of PPDC and first blood test after starting treatment were 614 (range: 204‒2890) and 516 (range: 135‒2706), respectively (b). A statistically significant difference was noted among the two corresponding groups, with P = 3.2 × 10–3 (b). For γ-GTP values, the median at the onset of PPDC and first blood test after starting treatment were 160 (range: 9‒1693) and 184 (range: 9‒1042), respectively (c). A statistically significant difference was noted among the two corresponding groups, with P = 0.016 (c)

Changes in the blood test values of (a) WBC, (b) ALP, and (c) γ-GTP at the onset of post-PD cholangitis and after starting the initial treatment. Blood test results showed changes in the (a) white blood cell (WBC) counts, (b) alkaline phosphatase (ALP) levels, and (c) gamma-glutamyl transpeptidase (γ-GTP) values at the onset of post-pancreaticoduodenectomy cholangitis (PPDC) and after starting the initial treatment. For WBC counts, the median at the onset of PPDC and first blood test after starting treatment were 10,385 (range: 4120‒21,690) and 6000 (range: 2570‒17,260), respectively (a). The Wilcoxon signed-rank sum test for the two corresponding groups showed a statistically significant difference with P = 1.2 × 10–6 (a). For ALP level, the median at the onset of PPDC and first blood test after starting treatment were 614 (range: 204‒2890) and 516 (range: 135‒2706), respectively (b). A statistically significant difference was noted among the two corresponding groups, with P = 3.2 × 10–3 (b). For γ-GTP values, the median at the onset of PPDC and first blood test after starting treatment were 160 (range: 9‒1693) and 184 (range: 9‒1042), respectively (c). A statistically significant difference was noted among the two corresponding groups, with P = 0.016 (c) Details of the blood culture tests are presented in Table 4. Blood culture tests were performed for 24 episodes; of these 24 tests, 16 (67%) yielded positive results. Blood culture test results were positive for 10 of 12 (83%) episodes with mild disease and 6 of 12 (50%) episodes with moderate disease. Escherichia coli was the most frequently detected pathogen in the blood culture samples.
Table 4

PPDC patients blood culture results

Blood cultures
Total number of inspections24
Number of tests positive (%)
Severity of PPDC
 Mild10 /12 (83)
 Moderate6 /12 (50)
Detected bacterial species and the number of detections by severity
Number of detections by severity of PPDC
BacteriaMildModerate
 Escherichia coli74
 Klebsiella pneumoniae22
 Aeromonas cavie20
 Enterococcus faecalis10
 Others42

PPDC post pancreaticoduodenectomy cholangitis

PPDC patients blood culture results PPDC post pancreaticoduodenectomy cholangitis A diagnosis of postoperative cholangitis often resulted in hospitalization for intravenous antibacterial therapy for a median of seven days (range, 3–31 days). There was no difference in the duration of antibiotic administration based on the severity of PPDC (Table 5). No cases progressed to severe disease after the commencement of treatment. Sulbactam/ampicillin (SBT/ABPC) was the most frequently used initial antibiotic regimen, and antimicrobial agents were changed for 11 episodes based on susceptibility, indicated by blood culture test results (Table 5).
Table 5

Details of the treatment of PPDC patients

Medication
Duration of medication (day)
All patients7 (3–31)a
Severity of PPDC
 Mild7 (3–26)a
 Moderate7 (5–31)a
Medication for PPDCNumber of events
Oral antibiotic treatment6
Intravenous antibiotic treatment27
Intravenous therapy followed by oral antibiotics3
Antibacterial agents
First antibacterial agent administeredNumber of events
Sulbactam / ampicillin21
Ceftriaxone5
Levofloxacin (oral antibiotics)6
Others4
Cases with subsequent change of antibiotics11

BD Endoscopic baloon dilation; SI Endoscopic stent insertion; EL Endoscopic lithotripsy; EO Endoscopic observation only

aData was presented as median (range)

Details of the treatment of PPDC patients BD Endoscopic baloon dilation; SI Endoscopic stent insertion; EL Endoscopic lithotripsy; EO Endoscopic observation only aData was presented as median (range) An endoscopic examination was performed for a total of four patients with repeated cholangitis or suspected anastomotic stricture (Table 5). Three of these four patients required treatment for anastomotic stenosis. One of these patients underwent a total of five endoscopic procedures, including balloon dilation, stent insertion, and stone extraction. For one patient with three recurrent cholangitis episodes, the endoscopic examination demonstrated that the hepaticojejunostomy site was sufficiently open with no stenosis or stones. Therefore, the cause was thought to be simple reflux. A univariate analysis of patients' preoperative, intraoperative, and postoperative characteristics was performed to determine their associations with the development of PPDC (Table 6). None of the characteristics was significantly associated with PPDC development. Postoperative pneumobilia was present in 75% of patients, but was not significantly associated with the occurrence of PPDC (Table 6).
Table 6

Predictors for the development of PPDC by univariate and multivariate analysis

CovariateCategoryPPDCUnivariateMultivariate
PositiveNegativeP valueOdds ratio (95%CI)P value
n = 19n = 157
Patient factors
Age (years)a71.7 (10.6)68.3 (9.90)0.151.04 (0.99–1.10)0.14
SexMale14960.281.86 (0.63–5.53)0.26
Female561
Body mass index (kg/m2)a22.7 (2.8)22.9 (3.2)0.86
ASA-PSI or II181471.00
III or IV110
Diabetes mellitusPositive3250.99
Negative16132
Diagnosis
 Pancreatic carcinoma9700.77
 Cholangiocarcinoma641
 Carcinoma of the ampulla of Vater121
 Others325
Preoperative jaundicePositive9730.94
Negative1084
Preoperative biliary drainagePositive12920.700.90 (0.32–2.58)0.85
Negative765
Preoperative cholangitisPositive5300.54
Negative14127
Operative factors
Operative time (min)a440 (94)449 (81)0.66
Blood loss (ml)b666 (28–1280)588 (10–2450)0.89
Blood transfusionPositive2310.53
Negative17126
Width of remnant bile duct (mm)a10.3 (3.2)10.8 (4.3)0.61
Biliary stentingPositive11830.67
Negative874
Postoperative factors
POPF Grade B or CPositive8760.63
Negative1181
DGEPositive090.60
Negative19148
Bile leakagePositive041.00
Negative19153
Postoperative pneumobiliaPositive171150.141.67 (0.45–6.22)0.45
Negative240

PPDC post pancreaticoduodenectomy cholangitis, CI confidence interval, ASA-PS American Society of Anesthesiologists Physical Status

aData were presented as mean (standard deviation)

bData were presented as median (range)

Predictors for the development of PPDC by univariate and multivariate analysis PPDC post pancreaticoduodenectomy cholangitis, CI confidence interval, ASA-PS American Society of Anesthesiologists Physical Status aData were presented as mean (standard deviation) bData were presented as median (range) In addition to age and sex, preoperative biliary drainage and postoperative pneumobilia were used as covariates in the multivariate analysis. The results of the multivariate analysis indicated that there were no significant predictive factors for PPDC development (Table 6).

Discussion

This study investigated the clinical characteristics of patients with PPDC treated at our institution and evaluated their severity and treatment. The results demonstrated that most cases of PPDC occurred within 2 years of surgery and that half of the cases involved recurrence. Although the positive rate of blood culture tests was high, there were no cases of severe PPDC. Furthermore, there were no significant predictive factors for the development of PPDC. Previous studies have reported that PPDC occurred in 6.7–36.1% of patients [15-19]. The details of PPDC treatment have been reported for 43 cases [15, 18, 19]. These studies showed that anastomotic stenosis was present in 16 cases (37%) and that many of them were treated endoscopically. Most cases without anastomotic stenosis were treated with antimicrobial agents. This study investigated the results of examinations for and treatment of PPDC. These results have not been previously described in detail. Based on the clinical course of PPDC examined during this study, we made the following observations regarding the pathogenesis and optimal treatment of PPDC: first, the pathogenesis of PPDC was discussed in the absence of any suspicious anastomotic stenosis of the hepaticojejunostomy; although the proportion of positive blood culture test results was high, there were no severe cases, and the biliary enzyme values, which were high at the time of onset, improved only with short-term antibiotic treatment. Therefore, it has been speculated that the pathogenesis of PPDC is due to a temporary increase in biliary pressure following the regurgitation of digestive juices. Stagnation of the flow of digestive juices in the jejunal loop can easily lead to reflux of digestive juices into the IHBD via anastomosis [18]. Shortening the jejunal loop to the minimum length necessary and adding the Braun's anastomosis may reduce pressure in the jejunal loop and prevent reflux of digestive fluids into the IHBD [20]. In contrast, impaired bile excretion in the IHBD is considered the pathogenesis for cases with anastomotic stenosis; moreover, this is also considered the pathogenesis for common acute cholangitis. Narrowing of the anastomosis of the hepaticojejunostomy may be accompanied by hepaticolithiasis, which may lead to a condition like common acute cholangitis. In this study, patients with recurrent cholangitis or suspected anastomotic stenosis were subjected to endoscopic examination and treatment that required multiple procedures; however, no severe cases were observed. Anastomotic stenosis may not be relieved by a single treatment; therefore, careful follow-up and the consideration of multiple possible procedures are recommended. Benign bile duct stenosis is the most common type of anastomotic stenosis; however, caution should be exercised in cases of possible malignant anastomotic recurrence. PPDC severity was classified according to the TG18 severity criteria. There was no significant difference between mild and moderate diseases in terms of the proportion of positive blood culture test results and treatment duration. Classifications of mild PPDC and moderate PPDC according to the TG18 may be equivalent in terms of the treatment and clinical course. The basis of treatment for PPDC, with or without anastomotic stenosis, is antibiotic administration. In this study, SBT/ABPC was often the first choice of antibacterial agent for PPDC and resulted in no cases of exacerbation. Additionally, SBT/ABPC can generally treat E. coli, which was frequently detected in blood culture samples in this study, and anaerobic bacteria such as Bacteroides fragilis. Therefore, it is conceivable that SBT/ABPC is a reasonable first choice for PPDC. Previous studies have shown that the overuse of SBT/ABPC has increased the resistant strains against SBT/ABPC in some areas; therefore, blood culture tests should be performed before the use of antibiotics to confirm the causative organism and drug sensitivity [10, 21]. For severe cases, we concur with the TG18 regarding the proposed use of metronidazole and clindamycin to treat B. fragilis with cholangitis after hepaticojejunostomy [10]. In this study, a short course of antimicrobial therapy resulted in clinical improvement even when Gram-negative bacilli, such as E. coli, were detected in blood culture samples. It has been reported that during the treatment of common acute cholangitis with Gram-negative bacilli, the antibiotic administration period could be shortened to less than two weeks, which is the conventional administration period if the source of infection is controlled, and we believe that this applies to the administration period for PPDC [22]. Regarding the route of administration, most patients in this study were hospitalized and treated with intravenous infusion. The TG18 indicated that oral antimicrobial therapy is also acceptable for common acute cholangitis depending on the patient’s ability of oral consumption [10]. For mild PPDC cases, follow-up with oral antibiotics in an outpatient clinic may be considered. One limitation of this study was that most of the cases were observed for more than one year but less than two years, which is an insufficient postoperative evaluation period. Additionally, we did not encounter any severe cases of PPDC. Moreover, this was a retrospective study performed at a single institution. To clarify the pathophysiology of PPDC, identify its possible predictors, and develop its disease-specific therapeutic recommendations, we believe prospective future studies are essential.

Conclusion

Most cases of PPDC occurred within two years of surgery, and half of the cases demonstrated recurrence. While the positive rate of blood culture tests was high, no severe cases were observed. The pathogenesis of PPDC may involve increased temporal pressure in the IHBD, which improves relatively promptly with antimicrobial treatment alone. Endoscopic examination should be considered for cases of recurrent cholangitis, which may be caused by an anastomotic stenosis.
  22 in total

1.  Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS).

Authors:  Moritz N Wente; Claudio Bassi; Christos Dervenis; Abe Fingerhut; Dirk J Gouma; Jakob R Izbicki; John P Neoptolemos; Robert T Padbury; Michael G Sarr; L William Traverso; Charles J Yeo; Markus W Büchler
Journal:  Surgery       Date:  2007-11       Impact factor: 3.982

Review 2.  The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After.

Authors:  Claudio Bassi; Giovanni Marchegiani; Christos Dervenis; Micheal Sarr; Mohammad Abu Hilal; Mustapha Adham; Peter Allen; Roland Andersson; Horacio J Asbun; Marc G Besselink; Kevin Conlon; Marco Del Chiaro; Massimo Falconi; Laureano Fernandez-Cruz; Carlos Fernandez-Del Castillo; Abe Fingerhut; Helmut Friess; Dirk J Gouma; Thilo Hackert; Jakob Izbicki; Keith D Lillemoe; John P Neoptolemos; Attila Olah; Richard Schulick; Shailesh V Shrikhande; Tadahiro Takada; Kyoichi Takaori; William Traverso; Charles R Vollmer; Christopher L Wolfgang; Charles J Yeo; Roberto Salvia; Marcus Buchler
Journal:  Surgery       Date:  2016-12-28       Impact factor: 3.982

3.  TG13: Updated Tokyo Guidelines for the management of acute cholangitis and cholecystitis.

Authors:  Tadahiro Takada; Steven M Strasberg; Joseph S Solomkin; Henry A Pitt; Harumi Gomi; Masahiro Yoshida; Toshihiko Mayumi; Fumihiko Miura; Dirk J Gouma; O James Garden; Markus W Büchler; Seiki Kiriyama; Masamichi Yokoe; Yasutoshi Kimura; Toshio Tsuyuguchi; Takao Itoi; Toshifumi Gabata; Ryota Higuchi; Kohji Okamoto; Jiro Hata; Atsuhiko Murata; Shinya Kusachi; John A Windsor; Avinash N Supe; SungGyu Lee; Xiao-Ping Chen; Yuichi Yamashita; Koichi Hirata; Kazuo Inui; Yoshinobu Sumiyama
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-01       Impact factor: 7.027

4.  Preoperative cholangitis during biliary drainage increases the incidence of postoperative severe complications after pancreaticoduodenectomy.

Authors:  Yuji Kitahata; Manabu Kawai; Masaji Tani; Seiko Hirono; Ken-ichi Okada; Motoki Miyazawa; Atsushi Shimizu; Hiroki Yamaue
Journal:  Am J Surg       Date:  2014-01-17       Impact factor: 2.565

5.  Late Biliary Complications after Pancreaticoduodenectomy.

Authors:  Pablo Parra-Membrives; Darío Martínez-Baena; Fabricio Sánchez-Sánchez
Journal:  Am Surg       Date:  2016-05       Impact factor: 0.688

6.  Short-course antimicrobial treatment for acute cholangitis with Gram-negative bacillary bacteremia.

Authors:  Shunsuke Uno; Ryota Hase; Masayoshi Kobayashi; Toshiyasu Shiratori; So Nakaji; Nobuto Hirata; Naoto Hosokawa
Journal:  Int J Infect Dis       Date:  2016-12-24       Impact factor: 3.623

7.  Effects of adding Braun jejunojejunostomy to standard Whipple procedure on reduction of afferent loop syndrome - a randomized clinical trial.

Authors:  Farzad Kakaei; Samad Beheshtirouy; Seyed Moahammad Reza Nejatollahi; Iqbal Rashidi; Touraj Asvadi; Afshin Habibzadeh; Mohammad Oliaei-Motlagh
Journal:  Can J Surg       Date:  2015-12       Impact factor: 2.089

8.  Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines.

Authors:  Keita Wada; Tadahiro Takada; Yoshifumi Kawarada; Yuji Nimura; Fumihiko Miura; Masahiro Yoshida; Toshihiko Mayumi; Steven Strasberg; Henry A Pitt; Thomas R Gadacz; Markus W Büchler; Jacques Belghiti; Eduardo de Santibanes; Dirk J Gouma; Horst Neuhaus; Christos Dervenis; Sheung-Tat Fan; Miin-Fu Chen; Chen-Guo Ker; Philippus C Bornman; Serafin C Hilvano; Sun-Whe Kim; Kui-Hin Liau; Myung-Hwan Kim
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-01-30

9.  Biliary complications after pancreaticoduodenectomy: skinny bile ducts are surgeons' enemies.

Authors:  Pauline Duconseil; Olivier Turrini; Jacques Ewald; Stéphane V Berdah; Vincent Moutardier; Jean-Robert Delpero
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

10.  Predictive factors of late cholangitis in patients undergoing pancreaticoduodenectomy.

Authors:  Yasuhiro Ito; Yuta Abe; Minoru Kitago; Osamu Itano; Yuko Kitagawa
Journal:  World J Surg Oncol       Date:  2018-01-31       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.